Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer’s disease dementia, mild cognitive impairment, and normal aging

OBJECTIVE: To evaluate the performance characteristics of florbetapir F 18 PET in patients with Alzheimer’s disease dementia (AD), mild cognitive impairment (MCI) and healthy control subjects (HC). METHODS: Florbetapir PET was acquired in 184 subjects (45 AD, 60 MCI, and 79 HC) within a multi-center...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Johnson, KA, Sperling, RA, Gidicsin, C, Carmasin, J, Maye, J, Coleman, RE, Reiman, EM, Sabbagh, MN, Sadowsky, CH, Fleisher, AS, Doraiswamy, PM, Carpenter, AP, Clark, CM, Joshi, AD, Lu, M, Grundman, M, Mintun, MA, Pontecorvo, MJ, Skovronsky, DM
Formato: Artigo
Idioma:Inglês
Publicado: 2013
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3800236/
https://ncbi.nlm.nih.gov/pubmed/23375563
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jalz.2012.10.007
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares